Assertio Holdings, Inc. Common Stock (ASRT)

Price$23.44

Value ScoreB

Growth ScoreD

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)104.74%

Price vs S&P 500 (4W)1.34%

VGM Score58.03

Market Capitalization$151.47M

All Metrics

P/CF (Annual)4.69x

Book Value / Share (Quarterly)$11.73

P/TBV (Annual)1.29x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.74%

Cash Flow / Share (Quarterly)$-1.10

Price vs S&P 500 (YTD)147.52%

Gross Margin (TTM)70.33%

Net Profit Margin (TTM)-34.94%

EPS (TTM)$-5.73

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-5.73

Revenue Growth (5Y)2.23%

EPS (Annual)$-4.74

ROI (Annual)-22.83%

Gross Margin (Annual)70.19%

Net Profit Margin (5Y Avg)-38.43%

Cash / Share (Quarterly)$11.10

Revenue Growth QoQ (YoY)-62.50%

ROA (Last FY)-11.38%

Revenue Growth TTM (YoY)-14.16%

EBITD / Share (TTM)$-1.25

ROE (5Y Avg)-48.68%

Operating Margin (TTM)-34.21%

Cash Flow / Share (Annual)$-4.39

P/B Ratio2.00x

P/B Ratio (Quarterly)1.62x

Net Income / Employee (Annual)$-573,100

EV / Revenue (TTM)1.54x

Net Interest Coverage (TTM)-222.43x

ROA (TTM)-13.32%

EV / EBITDA (TTM)348.14x

EPS Incl Extra (Annual)$-4.74

Current Ratio (Annual)1.70x

Quick Ratio (Quarterly)1.46x

3-Month Avg Trading Volume0.22M

52-Week Price Return134.50%

EV / Free Cash Flow (Annual)0.92x

Revenue / Employee (TTM)$1,927,500

Tangible BV / Share (Quarterly)$5.05

P/S Ratio (Annual)1.28x

Asset Turnover (Annual)0.44x

52-Week High$23.47

Operating Margin (5Y Avg)-35.52%

EPS Excl Extra (Annual)$-4.74

Tangible BV CAGR (5Y)-3.92%

26-Week Price Return116.13%

Quick Ratio (Annual)1.44x

13-Week Price Return94.28%

Total Debt / Equity (Annual)0.42x

Current Ratio (Quarterly)1.82x

Enterprise Value$157.01M

Revenue / Share Growth (5Y)35.51%

Asset Turnover (TTM)0.38x

Book Value / Share Growth (5Y)49.57%

Revenue / Employee (Annual)$2,239,900

Inventory Turnover (Annual)1.13x

Pretax Margin (Annual)-25.22%

Cash / Share (Annual)$9.87

3-Month Return Std Dev62.99%

Gross Margin (5Y Avg)79.18%

Net Income / Employee (TTM)$-673,400

ROE (Last FY)-32.33%

Net Interest Coverage (Annual)-81.93x

EPS Basic Excl Extra (Annual)$-4.74

P/FCF (TTM)5.48x

Receivables Turnover (TTM)1.60x

EV / Free Cash Flow (TTM)9.74x

Total Debt / Equity (Quarterly)0.52x

EPS Incl Extra (TTM)$-5.73

Receivables Turnover (Annual)1.36x

ROI (TTM)-27.18%

P/S Ratio (TTM)1.48x

Pretax Margin (5Y Avg)-38.02%

Revenue / Share (Annual)$18.54

Tangible BV / Share (Annual)$7.01

Forward P/E40.46x

Free OCF CAGR (5Y)-21.57%

Price vs S&P 500 (52W)107.46%

Year-to-Date Return158.54%

5-Day Price Return0.04%

EPS Normalized (Annual)$-4.74

ROA (5Y Avg)-21.75%

Net Profit Margin (Annual)-25.59%

Month-to-Date Return0.04%

Cash Flow / Share (TTM)$-2.28

EBITD / Share (Annual)$0.04

Operating Margin (Annual)-25.03%

LT Debt / Equity (Annual)0.42x

P/CF (TTM)9.68x

ROI (5Y Avg)-37.53%

LT Debt / Equity (Quarterly)0.52x

EPS Basic Excl Extra (TTM)$-5.73

P/TBV (Quarterly)3.78x

P/B Ratio (Annual)0.62x

Inventory Turnover (TTM)0.97x

Pretax Margin (TTM)-34.71%

Book Value / Share (Annual)$14.63

Price vs S&P 500 (13W)83.78%

Beta0.55x

P/FCF (Annual)5.74x

Revenue / Share (TTM)$15.88

ROE (TTM)-38.72%

52-Week Low$8.61

vGradeB

gGradeD

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-2.93est. -1.87

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.10

3.80

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ASRTAssertio Holdings, Inc. Common Stock	B	D	A	$23.44
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Assertio Holdings is a specialty pharmaceutical company focused on neurology and pain management. It markets three FDA-approved products: Gralise for postherpetic neuralgia, CAMBIA for acute migraine treatment, and Zipsor for mild to moderate pain relief.